Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label long-term safety study of VX-445 triple combination therapy in cystic fibrosis
MOH_2019-09-24_007413Phase 3Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of elexacaftor, tezacaftor and ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Sep 2019; status: active, not recruiting.
02
Drugs
elexacaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on MOH_2019-09-24_007413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-09-24_007413.